PT2575784T - Formas de dosagem oral de bendamustina - Google Patents

Formas de dosagem oral de bendamustina

Info

Publication number
PT2575784T
PT2575784T PT11727396T PT11727396T PT2575784T PT 2575784 T PT2575784 T PT 2575784T PT 11727396 T PT11727396 T PT 11727396T PT 11727396 T PT11727396 T PT 11727396T PT 2575784 T PT2575784 T PT 2575784T
Authority
PT
Portugal
Prior art keywords
bendamustine
dosage forms
oral dosage
oral
forms
Prior art date
Application number
PT11727396T
Other languages
English (en)
Inventor
Colledge Jeffrey
Olthoff Margaretha
Original Assignee
Astellas Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44243599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2575784(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Deutschland Gmbh filed Critical Astellas Deutschland Gmbh
Publication of PT2575784T publication Critical patent/PT2575784T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
PT11727396T 2010-06-02 2011-06-01 Formas de dosagem oral de bendamustina PT2575784T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10075231 2010-06-02
EP11075047 2011-03-14

Publications (1)

Publication Number Publication Date
PT2575784T true PT2575784T (pt) 2018-10-26

Family

ID=44243599

Family Applications (1)

Application Number Title Priority Date Filing Date
PT11727396T PT2575784T (pt) 2010-06-02 2011-06-01 Formas de dosagem oral de bendamustina

Country Status (25)

Country Link
US (2) US20130202693A1 (pt)
EP (1) EP2575784B1 (pt)
JP (2) JP6209446B2 (pt)
KR (1) KR101830142B1 (pt)
CN (1) CN103037851A (pt)
AR (1) AR081835A1 (pt)
AU (1) AU2011260615B2 (pt)
BR (1) BR112012030654B1 (pt)
CA (1) CA2800279A1 (pt)
CL (1) CL2012003341A1 (pt)
CO (1) CO6640318A2 (pt)
DK (1) DK2575784T3 (pt)
EA (1) EA031793B1 (pt)
ES (1) ES2690257T3 (pt)
IL (1) IL223311B (pt)
JO (1) JO3587B1 (pt)
MX (1) MX2012013872A (pt)
MY (1) MY173873A (pt)
NZ (1) NZ603872A (pt)
PL (1) PL2575784T3 (pt)
PT (1) PT2575784T (pt)
SG (1) SG186099A1 (pt)
TW (1) TWI500431B (pt)
WO (1) WO2011151087A1 (pt)
ZA (1) ZA201208823B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109157535A (zh) * 2012-02-14 2019-01-08 赛多斯有限责任公司 苯达莫司汀的制剂
EP2641592A1 (en) 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
EP3427721A1 (en) * 2012-05-18 2019-01-16 Genentech, Inc. High-concentration monoclonal antibody formulations
GB201212010D0 (en) * 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
MX2015005805A (es) 2012-11-12 2016-04-15 Ignyta Inc Derivados de bendamustina y métodos para utilizarlos.
WO2014078435A1 (en) 2012-11-14 2014-05-22 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (pt) * 1903-10-08 1905-03-16
US20030044434A1 (en) * 1997-07-29 2003-03-06 Ping Gao Self-emulsifying formulation for lipophilic compounds
FR2781373B1 (fr) * 1998-07-07 2001-09-21 Pf Medicament Formulations thixotropes pour le remplissage de gelules
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CA2455274A1 (en) 2001-04-10 2002-10-24 Zagros Pharma Limited Animal model for evaluating analgesics
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US7423004B2 (en) 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
EP1605916A4 (en) 2003-02-12 2012-02-22 R & P Korea Co Ltd SOLUBENT SOLVENT SYSTEM WITH SOLUBLE PEEL WITH IMPROVED ELUTION RATE
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CN101052396A (zh) * 2004-11-05 2007-10-10 赛福伦公司 癌症治疗
WO2006065392A2 (en) * 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
GB0526419D0 (en) 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
BRPI0713054A2 (pt) * 2006-06-30 2012-04-17 Mcneil Ppc Inc cápsulas sólidas enchidas com lìquido contendo ibuprofeno
AU2008237246B2 (en) * 2007-04-05 2014-06-05 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
JP2010533205A (ja) * 2007-07-12 2010-10-21 トラガラ ファーマシューティカルズ,インク. 癌、腫瘍、および腫瘍関連障害を治療するための方法および組成物
WO2009011861A1 (en) * 2007-07-16 2009-01-22 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
KR100913644B1 (ko) 2007-10-09 2009-08-24 제일약품주식회사 활성성분으로 시부트라민 유리염기를 함유하는 약제학적조성물 및 그 제조방법
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
US20110301177A1 (en) * 2008-06-06 2011-12-08 Boehringer Ingelheim International Gmbh Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
BRPI0922806B8 (pt) * 2008-12-03 2021-05-25 Astellas Deutschland Gmbh composição farmacêutica oral compreendendo bendamustina
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
CN102413816A (zh) * 2009-04-28 2012-04-11 赛福伦公司 苯达莫司汀的口服制剂
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter

Also Published As

Publication number Publication date
MY173873A (en) 2020-02-25
JP6373300B2 (ja) 2018-08-15
TW201210635A (en) 2012-03-16
ZA201208823B (en) 2014-01-29
JO3587B1 (ar) 2020-07-05
SG186099A1 (en) 2013-01-30
JP2013527207A (ja) 2013-06-27
AU2011260615A1 (en) 2013-01-10
DK2575784T3 (en) 2018-10-15
IL223311B (en) 2018-04-30
JP6209446B2 (ja) 2017-10-04
CN103037851A (zh) 2013-04-10
KR101830142B1 (ko) 2018-02-20
EP2575784B1 (en) 2018-08-08
ES2690257T3 (es) 2018-11-20
US10993933B2 (en) 2021-05-04
EA031793B1 (ru) 2019-02-28
TWI500431B (zh) 2015-09-21
CA2800279A1 (en) 2011-12-08
EP2575784A1 (en) 2013-04-10
PL2575784T3 (pl) 2019-03-29
US20130202693A1 (en) 2013-08-08
AU2011260615B2 (en) 2016-11-17
KR20130086157A (ko) 2013-07-31
EA201291104A1 (ru) 2013-06-28
BR112012030654B1 (pt) 2021-11-09
MX2012013872A (es) 2013-04-03
WO2011151087A1 (en) 2011-12-08
AR081835A1 (es) 2012-10-24
IL223311A0 (en) 2013-02-03
CL2012003341A1 (es) 2013-06-28
NZ603872A (en) 2014-07-25
JP2016153438A (ja) 2016-08-25
CO6640318A2 (es) 2013-03-22
US20150374670A1 (en) 2015-12-31
BR112012030654A2 (pt) 2016-08-16

Similar Documents

Publication Publication Date Title
HRP20161771T1 (hr) Formulacije bendamustina
IL272501A (en) Oral administration forms of bendamustine and their medical use
HRP20171421T1 (hr) Kruti oblici doziranja bendamustina
EP2563346A4 (en) SOLID ORAL PHARMACEUTICAL FORMS WITH TADALAFIL
EP2521515A4 (en) ORAL ORTHOSIS
IL213270A0 (en) Oral dosage forms of bendamustine
IL223311A0 (en) Oral dosage forms of bendamustine
HK1213785A1 (zh) 血管緊張素的口服製劑
HK1225609A1 (zh) 口服b12療法
EP2536688A4 (en) STABLE DOSAGE FORMS OF LEVOMILNACIPRAN
GB201018760D0 (en) An oral dosage form